Literature DB >> 3986813

Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

T J Melink, D D Von Hoff, J G Kuhn, M R Hersh, L A Sternson, T F Patton, R Siegler, D H Boldt, G M Clark.   

Abstract

Tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, TCAR, Riboxamide, NSC 286193) is a novel C-nucleoside with antitumor activity against several murine tumor models, including Lewis lung carcinoma. The mechanism whereby this compound exerts its antineoplastic effects is most likely related to a state of guanine nucleotide depletion whereby the anabolite, thiazole-4-carboxamide adenine dinucleotide, potently inhibits inosine-5'-monophosphate dehydrogenase. This Phase I study was designed to determine the maximally tolerated dose of Tiazofurin administered on a 5-day, every-28-day schedule. Tiazofurin levels were measured using a high-pressure liquid chromatography assay, and pharmacokinetic studies were performed in patients treated at each dose level. Nineteen patients received a total of 24 courses of the drug in doses ranging from 550 to 2200 mg/sq m. The dose-limiting toxicities were pleuropericarditis and a general illness best described as a "viral-like" syndrome (manifested by severe malaise, headaches, myalgias, fever, nausea, vomiting, and diarrhea). Other toxicity included myelosuppression, hyperuricemia, elevated serum creatine phosphokinase and serum glutamic oxaloacetic transaminase, conjunctivitis, mucositis, and desquamation of the palms of the hands. Plasma clearance of Tiazofurin followed a biexponential pattern with a harmonic mean terminal half-life of 7.6 h. The mean volume of distribution at steady state was 30 liters/sq m, and the mean plasma clearance was 3 liters/h/sq m. The total cumulative urinary excretion ranged from 15 to 49%. The maximally tolerated dose of Tiazofurin on a 5-day schedule was 1650 mg/sq m. The recommended dose for Phase II evaluations is 1100 mg/sq m for 5 days. However, exploration of other schedules which might allow administration of more Tiazofurin combined with biochemical studies including thiazole-4-carboxamide adenine dinucleotide measurements would be desirable.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3986813

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  New drug development for pediatric oncology.

Authors:  S Weitman; L Carlson; C B Pratt
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma.

Authors:  P Y Holoye; D T Carr; H M Dhingra; B S Glisson; J S Lee; W K Murphy; T Umsawasdi; D Jeffries
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

Review 3.  Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development.

Authors:  D D von Hoff
Journal:  Cancer Metastasis Rev       Date:  1988-12       Impact factor: 9.264

Review 4.  Clinical toxicity associated with tiazofurin.

Authors:  J L Grem; L Rubinstein; S A King; B D Cheson; M J Hawkins; D D Shoemaker
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

5.  Phase I study of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

Authors:  J A Maroun; D J Stewart
Journal:  Invest New Drugs       Date:  1990       Impact factor: 3.850

6.  Studies of purine and tiazofurin metabolism in drug sensitive human chronic myelogenous leukemia K 562 cells.

Authors:  K Pillwein; H N Jayaram; G Weber
Journal:  Blut       Date:  1988-08

7.  Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).

Authors:  R M Green; D J Stewart; J A Maroun
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

8.  Adenocarcinoma of unknown primary: retrospective analysis of chemosensitivity of 313 freshly explanted tumors in a tumor cloning system.

Authors:  A R Hanauske; G M Clark; D D Von Hoff
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

9.  Guanine ribonucleotide depletion inhibits T cell activation. Mechanism of action of the immunosuppressive drug mizoribine.

Authors:  L A Turka; J Dayton; G Sinclair; C B Thompson; B S Mitchell
Journal:  J Clin Invest       Date:  1991-03       Impact factor: 14.808

Review 10.  Anti-Tumor Potential of IMP Dehydrogenase Inhibitors: A Century-Long Story.

Authors:  Rand Naffouje; Punita Grover; Hongyang Yu; Arun Sendilnathan; Kara Wolfe; Nazanin Majd; Eric P Smith; Koh Takeuchi; Toshiya Senda; Satoshi Kofuji; Atsuo T Sasaki
Journal:  Cancers (Basel)       Date:  2019-09-11       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.